NEW YORK — Wall Street entered the final trading day of September with investors juggling a $20 billion defense contract, Robinhood’s attempt to turn artificial intelligence into a retail trading assistant, a brutal valuation warning on one of 2026’s hottest biotech stocks and another reminder that AI is reshaping everything from customer service to semiconductor testing.
The biggest premarket movers included:
Boeing
Robinhood
Moderna
Concentrix
FormFactor
and
Cal-Maine Foods.
But beneath those individual stock moves was a larger theme.
Investors were becoming increasingly selective.
Companies tied to:
Defense spending
AI infrastructure
and
new trading technology
received strong attention.
Meanwhile, richly valued stocks and companies showing deteriorating operating results were punished quickly.
That made September 30 a clear example of a market where headlines can move billions of dollars before the opening bell.
BOEING JUMPED AFTER WINNING A MASSIVE NAVY FIGHTER CONTRACT
Boeing shares climbed about:
2% in premarket trading
after the U.S. Navy selected the company to develop its next-generation:
F/A-XX fighter jet.
The initial development contract is worth more than:
$20 billion.
The aircraft will eventually replace the Navy’s aging:
F/A-18E/F Super Hornets
and
EA-18G Growlers.
That makes the award one of Boeing’s most important defense wins in years.
THE F/A-XX IS A SIXTH-GENERATION FIGHTER
The F/A-XX is expected to become a centerpiece of future U.S. carrier aviation.
The aircraft is designed to offer:
Longer range
Advanced stealth
Next-generation sensors
Networked weapons
and
Greater integration with unmanned aircraft.
Many technical details remain classified.
But the Navy describes the aircraft as a sixth-generation platform.
That places it beyond the current generation of fighters such as the:
F-35C.
BOEING BEAT NORTHROP GRUMMAN FOR THE CONTRACT
Northrop Grumman had also reportedly competed for the F/A-XX program.
Its shares fell approximately:
3.5% in premarket trading
after Boeing was selected.
That shows how strategically important the contract is.
A major fighter program can generate revenue for:
decades.
Development comes first.
Then testing.
Then production.
Then upgrades.
Then long-term maintenance.
The lifetime value can therefore become much larger than the initial contract.
THE PROGRAM COULD EVENTUALLY BE WORTH HUNDREDS OF BILLIONS
The initial contract covers development and test aircraft.
But if the Navy eventually purchases hundreds of fighters and international allies participate, the total program value could be dramatically larger.
That means investors were not simply reacting to:
$20 billion.
They were reacting to the possibility of an entirely new defense franchise.
For Boeing, that is particularly important because commercial aviation has faced years of:
Production disruptions
Certification delays
and
Cash-flow pressure.
Defense wins can help diversify the recovery.
BOEING NOW HAS BOTH MAJOR U.S. SIXTH-GENERATION FIGHTER PROGRAMS
The F/A-XX win follows another enormous defense victory.
In 2025, Boeing was selected to develop the U.S. Air Force’s:
F-47
next-generation fighter.
That means Boeing now holds development roles in both:
Air Force sixth-generation fighters
and
Navy sixth-generation fighters.
That is a remarkable turnaround.
Only a few years ago, analysts questioned whether Boeing’s fighter-jet business could eventually shrink as older programs ended.
Now its St. Louis defense operation has a much longer runway.
BOEING IS INVESTING HEAVILY IN ST. LOUIS
The company has spent billions expanding facilities designed for classified next-generation aircraft work.
Those investments include:
Advanced manufacturing
Secure production spaces
and
New engineering facilities.
The F/A-XX award validates some of that spending.
It also gives Boeing more reason to continue expanding defense manufacturing capacity.
BUT THE STOCK’S PREMARKET GAIN DID NOT FULLY HOLD
There is an important update.
Boeing’s premarket move was stronger than its final session performance.
The stock later finished slightly lower.
That shows investors are still balancing the defense win against several major risks.
These include:
Commercial airplane production
737 MAX certification issues
Labor negotiations
and
Cash flow.
One defense contract cannot immediately solve all of Boeing’s problems.
BOEING ALSO HAS A 737 MAX SOFTWARE ISSUE TO RESOLVE
A recently disclosed software problem affecting certain Boeing 737 MAX aircraft added another complication.
The issue involves automated flight-guidance functionality during a particular landing scenario.
U.S. Transportation Secretary Sean Duffy said the government currently does:
not consider it a flight-safety threat.
The FAA has not ordered the fleet grounded.
But certification work on the:
737 MAX 10
has been delayed while the software issue is reviewed.
That matters because Boeing still needs its commercial business to recover.
A LARGE UNION VOTE IS ANOTHER NEAR-TERM RISK
About:
17,000 Boeing engineers and technical workers
represented by SPEEA were also preparing to vote on a new contract.
A second rejection could potentially lead to a strike.
That could disrupt programs including:
737 MAX 10
and
777-9.
So while the Navy fighter award strengthens Boeing’s long-term defense outlook, investors still face near-term operational uncertainty.
ROBINHOOD ROSE AFTER UNVEILING AI TRADING AGENTS
Robinhood gained about:
2% before the opening bell
after unveiling one of its most ambitious product expansions.
The brokerage announced:
Robinhood Agents
an AI system that can:
Analyze markets
Create strategies
and
Place trades on behalf of users.
The company presented the product at its:
HOOD Summit 2026
in Houston.
CEO Vlad Tenev said Robinhood wants to bring tools once reserved for:
Hedge funds
Quantitative firms
and
Large financial institutions
to ordinary retail traders.
AI CAN NOW ACTUALLY TRADE FOR ROBINHOOD USERS
This is more than a chatbot that answers investing questions.
Users can create dedicated AI-driven trading accounts.
The agent can:
Research markets
Interpret information
Develop a strategy
and
Execute trades.
That represents a major shift.
Traditional retail brokerage software waits for customers to press:
Buy
or
Sell.
Agentic investing allows software to make decisions continuously.
That could fundamentally change how active retail trading works.
ROBINHOOD SAYS MORE THAN 150,000 CUSTOMERS ARE ALREADY USING AGENTIC TRADING
Robinhood launched an earlier version of agentic trading in:
May.
Since then, more than:
150,000 customers
have reportedly opened agentic accounts.
The AI systems now generate around:
30 million tool interactions per day.
That level of early adoption explains why Robinhood is expanding the product.
The company believes AI could make sophisticated strategies accessible to a much larger audience.
BUT USERS STILL CARRY THE INVESTMENT RISK
This is crucial.
If an AI agent makes a bad trade:
the customer bears the loss.
Robinhood does not guarantee investment performance.
AI systems can:
Misinterpret information
Overreact to noise
or
Use strategies that fail in changing market conditions.
That creates new regulatory and investor-protection questions.
An AI agent may be able to trade 24 hours a day.
That does not mean it can consistently beat the market.
ROBINHOOD ALSO WANTS WEEKEND STOCK TRADING
Another major announcement involved:
24/7 U.S. equity trading.
Robinhood already offers extended overnight trading during the week.
Now it wants customers to trade selected stocks:
on Saturdays
and
on Sundays.
The service is expected to launch after regulatory approvals.
This pushes the U.S. brokerage industry closer toward:
continuous markets.
THE STOCK MARKET MAY NO LONGER “CLOSE” IN THE TRADITIONAL SENSE
Global crypto markets already trade around the clock.
Foreign exchange trades almost continuously during the workweek.
U.S. equities remain centered around normal exchange hours.
Robinhood is trying to change that.
Other exchanges and brokers are also exploring longer trading windows.
The advantage is convenience.
A major geopolitical event on Saturday would no longer require investors to wait until Monday.
But there is a trade-off.
WEEKEND MARKETS COULD BE LESS LIQUID
Traditional trading hours concentrate:
Buyers
Sellers
and
Market makers
into the same period.
Weekend trading spreads those participants across more hours.
That could mean:
Wider bid-ask spreads
Lower liquidity
and
More volatile prices.
Retail traders may gain convenience but face poorer execution.
That is one of the biggest concerns surrounding round-the-clock stock markets.
ROBINHOOD IS ALSO BRINGING PERPETUAL FUTURES TO U.S. USERS
The company plans to offer:
perpetual futures
to eligible American customers.
These contracts are widely used in crypto markets.
Unlike traditional futures, they have:
no expiration date.
Traders can maintain leveraged exposure indefinitely as long as margin requirements are met.
Robinhood’s products could offer leverage of up to:
10 times
for some cryptocurrency contracts.
That creates more trading opportunities.
It also creates much greater risk.
LEVERAGE CAN MAGNIFY LOSSES EXTREMELY QUICKLY
Suppose a trader uses:
10x leverage.
A:
10% unfavorable market move
can theoretically wipe out most or all of the capital supporting that position.
That means perpetual futures are dramatically different from buying a normal stock.
Robinhood’s expansion increasingly positions it as a platform for:
active traders
rather than simply beginner investors.
THE COMPANY IS ADDING EARNINGS PREDICTION CONTRACTS TOO
Robinhood also plans to introduce contracts allowing customers to trade on outcomes involving corporate earnings.
Users might speculate on whether a company:
beats revenue estimates
or
hits another financial metric.
Those products blur the line between:
Traditional investing
Derivatives
and
Prediction markets.
Robinhood appears determined to become a one-stop platform for every type of active-market speculation.
WALL STREET ANALYSTS LIKED THE PRODUCT EXPANSION
Morgan Stanley maintained an:
Overweight
rating on Robinhood with a:
$150 price target.
Its analysts highlighted:
Agentic trading
and
U.S. perpetual futures
as particularly important products.
Deutsche Bank and KeyBanc also reacted positively to the broader product strategy.
Price targets are analyst opinions rather than guarantees.
But the reaction suggests Wall Street sees meaningful monetization potential.
BUT ROBINHOOD’S STOCK ENDED LOWER
The early optimism did not last.
Robinhood eventually closed approximately:
3.2% lower.
That looked like a classic:
“sell the news”
reaction.
The stock had already rallied substantially ahead of the HOOD Summit.
Investors may therefore have used the announcement as an opportunity to take profits.
That highlights an important market lesson:
A strong product announcement does not automatically mean a higher stock price.
Expectations matter.
MODERNA PLUNGED AFTER CITI SAID THE STOCK HAD GONE TOO FAR
Moderna moved in the opposite direction.
The biotech stock dropped more than:
6% in premarket trading
after Citigroup downgraded shares from:
Hold
to
Sell.
The reason was not failed clinical data.
It was:
valuation.
That makes the call particularly interesting.
Moderna had become one of the most explosive stocks of 2026 after reporting major success in its personalized cancer-vaccine program.
MODERNA HAD RISEN MORE THAN 500% IN 2026
Before the downgrade, Moderna shares had climbed:
more than fivefold
during the year.
Some estimates put the gain above:
600%.
The rally intensified after Moderna and Merck announced successful late-stage results for their personalized mRNA cancer therapy:
intismeran autogene.
The treatment is being studied in combination with:
Merck’s Keytruda.
In a Phase 3 melanoma study, the combination met its major endpoints involving:
recurrence-free survival
and
distant metastasis-free survival.
That result transformed investor expectations for Moderna.
CITI DID NOT QUESTION THE SCIENCE — IT QUESTIONED THE PRICE
Citigroup analyst Geoff Meacham argued Moderna’s valuation had become difficult to justify.
Citi cut the stock to:
Sell
and set an:
$80 price target.
Moderna had been trading near:
$200.
That implied potential downside of around:
60%.
The call was one of the most bearish recommendations on Wall Street.
But the key argument was not that the cancer vaccine would fail.
The argument was that investors were already pricing in:
too much future success.
CITI SAYS MODERNA WOULD NEED AN ENORMOUS ONCOLOGY BUSINESS
The analyst estimated that Moderna’s valuation could require roughly:
$26 billion in annual oncology sales
to make economic sense.
And Moderna would not keep all of that revenue.
Its personalized cancer vaccine is being developed with:
Merck.
The economics are shared.
That means Moderna needs extremely large commercial adoption to justify an $80-billion-plus market capitalization.
Citi argued that expectation was too aggressive.
MELANOMA SUCCESS DOES NOT GUARANTEE SUCCESS IN EVERY CANCER
This is one of the biggest scientific uncertainties.
Melanoma is considered highly:
immunogenic.
That means the immune system can often recognize tumor mutations relatively effectively.
Personalized cancer vaccines may therefore work particularly well there.
But other cancers can be harder.
Investors are hoping the same mRNA platform succeeds in:
Lung cancer
Kidney cancer
and
other solid tumors.
That is possible.
It is not yet proven.
OCTOBER DATA COULD BECOME THE NEXT MAJOR CATALYST
Moderna and Merck are expected to present more detailed cancer-vaccine data at:
ESMO in October.
That could determine whether the stock’s massive rally regains momentum or whether valuation concerns deepen.
Clinical-stage biotechnology stocks often trade on future expectations.
When expectations become extremely high, even good data may not be enough.
That is the risk Moderna now faces.
MODERNA’S LONG-TERM STORY HAS CHANGED DRAMATICALLY
Only a few years ago, Moderna was heavily dependent on:
Covid-19 vaccines.
Pandemic demand collapsed.
Revenue fell.
The company cut costs.
Investors questioned whether mRNA technology could produce another blockbuster.
Now Moderna has:
an approved RSV vaccine
the first FDA-approved mRNA seasonal flu vaccine
and
a promising personalized cancer vaccine.
That is a major strategic transformation.
But the stock price may have transformed even faster.
CONCENTRIX PLUNGED NEARLY 10% PREMARKET
Concentrix fell roughly:
9.5%
after reporting fiscal third-quarter results.
The customer-service and technology outsourcing company generated:
$2.454 billion
in revenue.
That was down:
1.2% year over year
and slightly below Wall Street expectations.
Adjusted earnings were:
$2.92 per share.
That exceeded analyst forecasts around:
$2.71.
So the quarter was not uniformly weak.
The biggest concern was:
growth.
AI IS DISRUPTING CONCENTRIX’S TRADITIONAL BUSINESS
Concentrix provides:
Customer support
Technology services
and
Business-process outsourcing.
These are areas increasingly vulnerable to generative AI.
AI agents can answer customer questions automatically.
They can summarize calls.
They can perform routine back-office work.
That creates an obvious threat to traditional labor-intensive outsourcing.
But Concentrix says it is deliberately disrupting its own business.
HALF OF CONCENTRIX REVENUE NOW COMES FROM RECENTLY WON BUSINESS
CEO Chris Caldwell said approximately:
50% of company revenue
now comes from business won and deployed within the past:
three years
since AI adoption accelerated.
That is a striking statistic.
It suggests Concentrix is replacing old work with new AI-enabled services.
The transition may eventually strengthen the company.
But it creates short-term pressure on revenue.
THE COMPANY REPORTED A $910 MILLION ACCOUNTING LOSS
Concentrix reported a GAAP operating loss of:
$910.3 million.
That looks catastrophic.
But investors should understand why.
The loss included a:
$1.05 billion goodwill impairment.
That was a noncash accounting charge tied largely to the company’s lower market valuation.
On a non-GAAP basis, operating income was:
$309 million
up:
1.3%.
That distinction is essential.
The business did not literally lose $910 million of operating cash.
FREE CASH FLOW WAS STRONG
Concentrix generated:
$268 million
of operating cash flow during the quarter.
Adjusted free cash flow reached:
$218 million.
Management expects approximately:
$630 million to $650 million
of adjusted free cash flow for the full fiscal year.
The company also increased its quarterly dividend.
That means the stock’s decline reflected concerns about revenue growth rather than immediate liquidity problems.
CONCENTRIX EXPECTS Q4 REVENUE TO DECLINE
The company expects fourth-quarter reported revenue between:
$2.41 billion
and
$2.46 billion.
That implies a constant-currency revenue decline of roughly:
3% to 5%.
For the full year, revenue is expected to be approximately:
$9.83 billion to $9.88 billion.
Investors want evidence that new AI-enabled services will eventually grow faster than traditional work declines.
Until then, Concentrix may remain caught between:
AI disruption
and
AI opportunity.
FORMFACTOR ROSE AFTER A NEW BUY RATING
FormFactor gained approximately:
1% before the bell
after Deutsche Bank initiated coverage with a:
Buy
rating.
The brokerage later saw much stronger gains during regular trading.
Shares eventually jumped about:
9.6%.
Deutsche Bank set a:
$200 price target.
The bullish thesis revolves around:
AI semiconductor testing.
FORMFACTOR MAKES CHIP-TESTING EQUIPMENT
FormFactor makes:
probe cards
and
semiconductor test systems.
These tools test chips during the manufacturing process.
Testing has become increasingly important as advanced AI processors become:
More expensive
More complex
and
More tightly packaged.
A defective chip can cost thousands of dollars.
Finding defects earlier can therefore save significant money.
NVIDIA COULD BECOME AN IMPORTANT CUSTOMER DRIVER
Deutsche Bank highlighted FormFactor’s position as a potential secondary supplier of probe cards used in testing:
Nvidia GPUs
manufactured at:
TSMC.
The company is expected to begin generating revenue from that opportunity during the second half of 2026.
If Nvidia continues expanding Blackwell and Rubin production, the amount of testing required also increases.
That creates an indirect AI opportunity for FormFactor.
HIGH-BANDWIDTH MEMORY IS ANOTHER MAJOR CATALYST
AI accelerators require:
high-bandwidth memory, or HBM.
HBM is one of the fastest-growing parts of the semiconductor industry.
FormFactor has significant exposure to HBM testing.
As Nvidia, AMD and custom-AI-chip manufacturers use more memory per accelerator, semiconductor test complexity grows.
That gives FormFactor another path to benefit from the AI infrastructure boom.
FORMFACTOR’S PROFITS ARE ALREADY GROWING RAPIDLY
In its previous quarter, FormFactor reported adjusted earnings of:
82 cents per share.
That was up more than:
200% year over year.
Revenue increased approximately:
32%
to:
$258.2 million.
Analysts expect further growth.
That gives investors fundamental evidence behind the AI-test-equipment story.
CAL-MAINE FOODS FELL AFTER EGG PROFITS COLLAPSED
Cal-Maine Foods dropped roughly:
6.5% before the market opened.
The largest egg producer in the United States reported a dramatic reversal from the extraordinary profits generated during the previous egg-price boom.
Fiscal first-quarter revenue fell:
41.5%
to approximately:
$539.6 million.
A year earlier, revenue was:
$922.6 million.
The reason was simple:
egg prices collapsed.
CAL-MAINE SWUNG TO AN OPERATING LOSS
Gross profit nearly disappeared.
Cal-Maine reported gross profit of only around:
$403,000
compared with:
$311 million
a year earlier.
The company posted an operating loss of approximately:
$82.2 million.
That compared with operating income of:
$249.2 million
the previous year.
Few industries demonstrate commodity-cycle volatility as clearly as eggs.
EGG PRICES HAD PREVIOUSLY SURGED
During earlier periods of:
avian influenza
and
supply shortages,
egg prices increased dramatically.
That produced extraordinary profitability for Cal-Maine.
But egg production recovered.
Supply expanded.
Prices fell.
The company’s earnings therefore normalized extremely quickly.
That is why investors should be cautious about valuing commodity-sensitive businesses using peak-cycle profits.
CAL-MAINE IS TRYING TO REDUCE THAT VOLATILITY
The company is expanding into:
specialty eggs
and
prepared foods.
It wants to become less dependent on conventional commodity egg pricing.
Specialty products include:
Cage-free eggs
Free-range eggs
Pasture-raised eggs
and
Organic eggs.
Prepared-food acquisitions are also increasing diversification.
The goal is to create a more predictable earnings base.
BUT CONVENTIONAL EGG PRICES STILL DOMINATE RESULTS
The first-quarter collapse shows the transformation is not complete.
Cal-Maine remains highly sensitive to:
Egg supply
Avian influenza
Feed costs
and
Wholesale pricing.
When conventional egg prices fall sharply, prepared foods and specialty products cannot yet completely offset the decline.
That explains the stock’s negative reaction.
THE BROADER MARKET BACKDROP WAS ALREADY DIFFICULT
September 30 was also shaped by macroeconomic data.
U.S. inflation came in somewhat softer than feared.
The Personal Consumption Expenditures price index increased:
3.4% year over year.
That was below expectations near:
3.7%.
The softer data reduced expectations for an immediate Federal Reserve rate increase.
But Treasury yields remained elevated.
That kept pressure on valuations.
THE S&P 500 STILL FINISHED LOWER
Despite softer inflation, the S&P 500 slipped approximately:
0.25%.
The Dow fell around:
0.86%.
The Nasdaq performed better but remained volatile.
That backdrop explains why several stocks that initially rose before the open eventually reversed.
Investors were not simply buying every positive headline.
They were demanding stronger evidence.
SEPTEMBER 30 SHOWED FOUR DIFFERENT WAYS A STOCK CAN MOVE
The premarket movers offered an unusually clear lesson.
Boeing rose because it won a massive government contract.
Robinhood rose because investors liked new products and AI functionality.
FormFactor rose because analysts identified a new AI-driven earnings opportunity.
Meanwhile:
Moderna fell because valuation outran fundamentals.
Concentrix fell because revenue growth remained weak.
Cal-Maine fell because the commodity cycle reversed.
These are completely different catalysts.
But they all demonstrate the same principle:
Stock prices move on changes in future expectations.
THE AI THEME CONNECTED ROBINHOOD, CONCENTRIX AND FORMFACTOR
Artificial intelligence ran through several of the day’s stories.
Robinhood is using AI to:
automate investing.
Concentrix is using AI to:
rebuild customer-service outsourcing.
FormFactor benefits because AI chips require:
more sophisticated semiconductor testing.
Three completely different sectors.
One technology cycle.
That demonstrates how deeply AI is spreading through the economy.
BUT THE IMPACT OF AI IS NOT THE SAME FOR EVERY COMPANY
This is the crucial distinction.
For Robinhood, AI may create:
new products
and
more trading activity.
For FormFactor, AI creates:
higher equipment demand.
For Concentrix, AI may simultaneously:
destroy old revenue
and
create new revenue.
Investors therefore cannot simply buy any company mentioning artificial intelligence.
They need to understand whether AI actually improves the business model.
BOEING’S STORY IS ALMOST THE OPPOSITE
Boeing’s catalyst had little to do with AI mania.
Its advantage comes from something much older:
national defense spending.
But sixth-generation aircraft will themselves rely heavily on:
AI
Autonomy
Advanced sensors
and
Networked warfare.
So even traditional defense companies are increasingly becoming technology platforms.
That overlap is one reason defense spending remains a major investment theme.
MODERNA SHOWS WHY GREAT NEWS CAN STILL PRODUCE A FALLING STOCK
Moderna may provide the most important lesson of the day.
The company’s cancer-vaccine data were objectively positive.
Its scientific outlook improved.
Yet the stock fell sharply.
Why?
Because the share price had already risen:
more than 500%.
When expectations become extreme, investors begin demanding even stronger evidence.
A good company can become a bad stock at the wrong valuation.
Conversely, a troubled company can become an attractive stock if expectations become low enough.
PREMARKET MOVES ARE NOT FINAL VERDICTS
September 30 also demonstrated why premarket trading should be interpreted carefully.
Robinhood gained before the bell.
Then closed lower.
Boeing gained before the bell.
Then finished slightly down.
FormFactor started with a modest gain.
Then surged nearly:
10%.
Premarket markets contain less liquidity than normal trading hours.
Prices can therefore move sharply once full market participation begins.
The opening bell can completely change the story.
THE BIGGER STORY: WALL STREET IS REWARDING CATALYSTS — BUT PUNISHING EXPECTATIONS EVEN FASTER
The September 30 premarket session looked like a random collection of stock moves.
It wasn’t.
It reflected a market becoming increasingly demanding.
Boeing received a $20 billion defense award.
Robinhood unveiled AI agents and weekend trading.
FormFactor gained another pathway into the AI chip supply chain.
Those stories offered investors new sources of future revenue.
But Moderna demonstrated the opposite side of the market.
A spectacular scientific breakthrough and a 500%-plus rally created expectations so high that one analyst’s valuation warning could erase billions of dollars in market value.
Concentrix showed how AI can simultaneously create opportunity and destroy legacy businesses.
And Cal-Maine showed how quickly record commodity profits can disappear when supply conditions normalize.
That is the environment investors are entering.
High Treasury yields mean money is no longer free.
AI enthusiasm means growth expectations are enormous.
And valuations increasingly require companies to deliver real cash flow rather than simply exciting narratives.
On September 30, Boeing won a future fighter program, Robinhood unveiled a future trading platform and Moderna defended a future cancer franchise — but Wall Street’s message was clear: having a compelling future is no longer enough if investors believe too much of it is already priced in.
